keyword
MENU ▼
Read by QxMD icon Read
search

renal cancer model

keyword
https://www.readbyqxmd.com/read/28212559/the-selective-mek1-inhibitor-selumetinib-enhances-the-antitumor-activity-of-everolimus-against-renal-cell-carcinoma-in-vitro-and-in-vivo
#1
Yun Zou, Jianfeng Wang, Xuejiao Leng, Jiwei Huang, Wei Xue, Jin Zhang, Yiran Huang
Renal cell carcinoma (RCC) is a urologic malignant cancer and often diagnosed at an advanced stage, which results in high mortality. Targeted therapy may improve the quality of life and survival of patients who are not suitable for nephrectomy. Everolimus, an mTOR inhibitor, is currently used as sequential or second-line therapy for RCC refractory to Sunitinib or sorafenib. However, its efficiency is palliative. In this study, we evaluated whether the antitumor activity of everolimus against RCC is enhanced by Selumetinib, a selective MEK1 inhibitor...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28197812/mcpip1-contributes-to-clear-cell-renal-cell-carcinomas-development
#2
Janusz Ligeza, Paulina Marona, Natalia Gach, Barbara Lipert, Katarzyna Miekus, Waclaw Wilk, Janusz Jaszczynski, Andrzej Stelmach, Agnieszka Loboda, Jozef Dulak, Wojciech Branicki, Janusz Rys, Jolanta Jura
Monocyte Chemoattractant protein-induced protein 1 (MCPIP1), also known as Regnase-1, is encoded by the ZC3H12a gene, and it mediates inflammatory processes by regulating the stability of transcripts coding for proinflammatory cytokines and controlling activity of transcription factors, such as NF-κB and AP1. We found that MCPIP1 transcript and protein levels are strongly downregulated in clear cell renal cell carcinoma (ccRCC) samples, which were derived from patients surgically treated for renal cancer compared to surrounded normal tissues...
February 14, 2017: Angiogenesis
https://www.readbyqxmd.com/read/28195651/early-estimates-of-seer-cancer-incidence-2014
#3
Denise Riedel Lewis, Huann-Sheng Chen, Myles G Cockburn, Xiao-Cheng Wu, Antoinette M Stroup, Douglas N Midthune, Zhaohui Zou, Martin F Krapcho, Daniel G Miller, Eric J Feuer
BACKGROUND: Cancer incidence rates and trends for cases diagnosed through 2014 using data reported to the Surveillance, Epidemiology, and End Results (SEER) program in February 2016 and a validation of rates and trends for cases diagnosed through 2013 and submitted in February 2015 using the November 2015 submission are reported. New cancer sites include the pancreas, kidney and renal pelvis, corpus and uterus, and childhood cancer sites for ages birth to 19 years inclusive. METHODS: A new reporting delay model is presented for these estimates for more consistent results with the model used for the usual November SEER submissions, adjusting for the large case undercount in the February submission...
February 14, 2017: Cancer
https://www.readbyqxmd.com/read/28187463/preoperative-albumin-to-globulin-ratio-predicts-survival-in-clear-cell-renal-cell-carcinoma-patients
#4
Zhen Chen, Yingjie Shao, Hongwei Yao, Qianfeng Zhuang, Kun Wang, Zhaoyu Xing, Xianlin Xu, Xiaozhou He, Renfang Xu
In this retrospective analysis, we evaluated associations between albumin to globulin ratio (AGR), clinicopathological characteristics, and survival in 592 patients with localized or locally advanced clear cell renal cell carcinoma (CCRCC) prior to nephrectomy. We found that low AGR was associated with more aggressive tumor behavior; patients with low AGR had poorer overall survival (OS) and cancer-specific survival (CSS) in Kaplan-Meier survival analyses both before and after propensity score matching, which was used to compensate for differences in baseline clinicopathological characteristics...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28178644/clinicalpathological-and-prognostic-significance-of-survivin-expression-in-renal-cell-carcinoma-a-meta-analysis
#5
Zhichen Pu, Guang-Zhen Wu, QiFei Wang
BACKGROUND: In recent years, survivin expression had been investigated as a prognostic biomarker for renal cell carcinoma (RCC), however, the results were conflicting. This study was aimed to explore the association between survivin expression and clinicalpathological features and the prognostic value for cancer-specific survival (CSS) and overall survival (OS) in RCC. RESULTS: Eleven studies with 1,697 subjects were included in this meta-analysis. The results showed that survivin expression was associated with higher tumor grade (OR=4...
February 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28166101/comparative-effect-of-initiating-metformin-versus-sulfonylureas-on-breast-cancer-risk-in-older-women
#6
Jin-Liern Hong, Michele Jonsson Funk, John Buse, Louise M Henderson, Jennifer L Lund, Virginia Pate, Til Stürmer
BACKGROUND: Several observational studies have reported that metformin may be associated with reduced risk of breast cancer; however, many of these studies were affected by time-related biases such as immortal time bias and time-window bias. This study aimed to examine the relative risk of breast cancer for older women initiating metformin versus sulfonylureas while avoiding such biases. METHODS: The study cohort consisted of women aged 65+ who initiated monotherapy with metformin (n=45,900) or sulfonylureas (n=13,904) and were free of cancer and renal disease within 6 months before treatment initiation using 2007-2012 US Medicare claims data...
February 3, 2017: Epidemiology
https://www.readbyqxmd.com/read/28162771/experimental-murine-model-of-renal-cancer
#7
B Padilla-Fernández, M B García-Cenador, P Rodríguez-Marcos, J F López-Marcos, P Antúnez-Plaza, J M Silva-Abuín, D López-Montañés, F J García-Criado, M F Lorenzo-Gómez
INTRODUCTION: The objective of this study was to determine the reproducibility in a murine model of renal tumours of various histological strains that could be useful for investigating the response to target drugs. MATERIAL AND METHODS: Development and analysis of the "in vivo" model: tumour xenograft of renal cell carcinomas with Balb/c nude athymic mice. Nontumourous human renal tissue was implanted in the interscapular region of 5 mice, chromophobe renal cell carcinoma was implanted in 5 mice (which, after checking its growth, was prepared for implantation in another 10 mice) and Fuhrman grade 2 clear cell renal cell carcinoma (CCRCC) was implanted in 5 mice (which was also subsequently implanted in 10 mice)...
February 2, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28159640/focused-ultrasound-triggered-release-of-tyrosine-kinase-inhibitor-from-thermosensitve-liposomes-for-treatment-of-renal-cell-carcinoma
#8
Caleb Abshire, Hakm Y Murad, Jaspreet S Arora, James Liu, Sree Harsha Mandava, Vijay T John, Damir B Khismatullin, Benjamin R Lee
This study reports, for the first time, development of tyrosine kinase inhibitor-loaded, thermosensitive liposomes (TKI/TSLs) and their efficacy for treatment of renal cell carcinoma when triggered by focused ultrasound (FUS). Uptake of these nanoparticles into renal cancer cells was visualized with confocal and fluorescent imaging of rhodamine B-loaded liposomes. The combination of TKI/TSLs and focused ultrasound was tested in an in vitro tumor model of renal cell carcinoma. According to MTT cytotoxic assay and flow cytometric analysis the combined treatment led to the least viability (23...
January 31, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28159493/alcohol-consumption-and-the-risk-of-renal-cancers-in-the-european-prospective-investigation-into-cancer-and-nutrition-epic-wozniak-mb-brennan-p-brenner-dr-overvad-k-olsen-a-tj%C3%A3-nneland-a-boutron-ruault-mc-clavel-chapelon-f-fagherazzi-g-katzke-v-k%C3%A3-hn-t-boeing
#9
Raman Jay, P Brennan, Brenner, K Overvad, A Olsen, A Tjønneland, M C Boutron-Ruault, F Clavel-Chapelon, Fagherazzi, V Katzke, T Kühn, H Boeing, M M Bergmann, A Steffen, A Naska, A Trichopoulou, D Trichopoulos, C Saieva, S Grioni, S Panico, R Tumino, P Vineis, H B Bueno-de-Mesquita, P H Peeters, A Hjartåker, E Weiderpass, L Arriola, E Molina-Montes, E J Duell, C Santiuste, R Alonso de la Torre, A Barricarte Gurrea, T Stocks, M Johansson, B Ljungberg, N Wareham, K T Khaw, R C Travis, A J Cross, N Murphy, E Riboli, G Scelo
Epidemiologic studies have reported that moderate alcohol consumption is inversely associated with the risk of renal cancer. However, there is no information available on the associations in renal cancer subsites. From 1992 to 2010, 477,325 men and women in the European Prospective Investigation into Cancer and Nutrition cohort were followed for incident renal cancers (n = 931). Baseline and lifetime alcohol consumption was assessed by country-specific, validated dietary questionnaires. Information on past alcohol consumption was collected by lifestyle questionnaires...
January 31, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28156631/survival-benefits-among-patients-with-end-stage-renal-disease-receiving-dialysis-versus-no-dialysis
#10
Maen Abdelrahim, Valda D Page, Shouhao Zhou, Chan Shen, Sriram Yennu, Bo Zhao, Joanna-Grace Mayo Manzano, Marina Ciny George, Joseph L Nates, Alvin Howard Moss, Rima Pai, Ala Abudayyeh
: 55 Background: Retrospective study of the outcomes of Stage IV Cancer Patients with End Stage Renal disease Receiving Dialysis and comparing the survival benefits among the patients who received Hemodialysis versus who didn't at a Comprehensive Cancer Center. METHODS: Retrospectively review all patients admitted to MDACC from 2005-2014 and diagnosed with stage IV solid tumor admitted with Acute kidney injury and a nephrology consult were included (N = 903) 19...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156480/effect-of-red-blood-cell-transfusions-on-patient-reported-outcomes-in-an-ambulatory-oncology-population
#11
Kimberly D Moeller, Lawrence David Wagman
: 78 Background: The standard transfusion (Tf) trigger in the hospitalized patient is hemoglobin (Hgb) level driven. Triggers in the ambulatory oncology population are often symptom based. The symptoms of exercise intolerance (EI), fatigue (F), and shortness of breath (SOB) were identified from a hospital quality review. The purpose of this study was to evaluate patient reported symptom (SX) changes following red blood cell (RBC) Tf. METHODS: Standardized Tf orders required symptom indication(s) which include EI, F, SOB and Other...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28155630/lndriver-identifying-driver-genes-by-integrating-mutation-and-expression-data-based-on-gene-gene-interaction-network
#12
Pi-Jing Wei, Di Zhang, Junfeng Xia, Chun-Hou Zheng
BACKGROUND: Cancer is a complex disease which is characterized by the accumulation of genetic alterations during the patient's lifetime. With the development of the next-generation sequencing technology, multiple omics data, such as cancer genomic, epigenomic and transcriptomic data etc., can be measured from each individual. Correspondingly, one of the key challenges is to pinpoint functional driver mutations or pathways, which contributes to tumorigenesis, from millions of functional neutral passenger mutations...
December 23, 2016: BMC Bioinformatics
https://www.readbyqxmd.com/read/28154780/human-endogenous-retroviruses-and-cancer
#13
María Gonzalez-Cao, Paola Iduma, Niki Karachaliou, Mariacarmela Santarpia, Julià Blanco, Rafael Rosell
Human endogenous retroviruses (HERVs) are retroviruses that infected human genome millions of years ago and have persisted throughout human evolution. About 8% of our genome is composed of HERVs, most of which are nonfunctional because of epigenetic control or deactivating mutations. However, a correlation between HERVs and human cancer has been described and many tumors, such as melanoma, breast cancer, germ cell tumors, renal cancer or ovarian cancer, express HERV proteins, mainly HERV-K (HML6) and HERV-K (HML2)...
December 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28152835/physician-decisions-related-to-maintenance-therapy-for-advanced-non-small-cell-lung-cancer-nsclc-in-the-united-states-us
#14
Sarah Goring, Kerstin Mueller, Lisa M Hess, Ana Belen Oton, Catherine Muehlenbein, Yajun Zhu, Himani Aggarwal, Mohamed K Mohamed, Benjamin Philip Levy, Katherine B Winfree
: 182 Background: In 2006, maintenance therapy was added as a treatment guideline for patients with advanced non-squamous (nsq) NSCLC. This study aimed to identify patient- and disease-related factors that impact maintenance therapy decision making. METHODS: An online discrete choice survey was administered to physicians currently managing patients with advanced nsq NSCLC in the US. Physicians viewed 12 patient profiles differing in levels of the following attributes: 1st line treatment response (complete, partial, stable, progression), adverse events during 1st line therapy (none, mild, moderate, severe), comorbidities (none, mild renal, severe renal, other), patient motivation/convenience (+/+, +/-, -/+, -/-), patient insurance co-pay rate (0, 5, 10, 20%), and age (45, 58, 68, 80 years)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152737/financial-risk-sharing-agreements-using-options-to-make-marginal-benefits-cost-effective
#15
(no author information available yet)
: 41 Background: New cancer treatments have become increasingly costly. Although new drugs may be sufficiently cost-efficiency for a primary indication (i1) to receive funding, subsequent indications (ia) may not prove cost-effective. A financial risk-sharing agreement to increase access is proposed. A potential 2012 real-world implementation in Canada for pazopanib use in metastatic renal cell carcinoma (mRCC) as i1, and soft-tissue sarcoma (STS) as ia is presented. METHODS: The market value of an indication can be approximated by its net-present-value (NPV) of expected cash flows...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28146604/the-clinically-used-poly-adp-ribose-polymerase-parp-inhibitor-olaparib-improves-organ-function-suppresses-inflammatory-responses-and-accelerates-wound-healing-in-a-murine-model-of-third-degree-burn-injury
#16
Akbar Ahmad, Gabor Olah, David N Herndon, Csaba Szabo
BACKGROUND AND PURPOSE: The PARP inhibitor olaparib has recently been approved for human use for the therapy of cancer. Considering the role of PARP in critical illness, we tested the effect of olaparib in a murine model of burn injury, in order to begin exploring the feasibility of repurposing olaparib for the therapy of burn patients. EXPERIMENTAL APPROACH: Mice were subjected to scald burn injury and randomized into vehicle or olaparib (10 mg/kg/day i.p.) groups...
February 1, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28143997/targeted-therapy-for-metastatic-renal-cell-carcinoma
#17
REVIEW
Andika Afriansyah, Agus Rizal Ah Hamid, Chaidir A Mochtar, Rainy Umbas
In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has provided a new hope and significantly enhanced the prognosis of the disease. Three class of targeted therapy were developed, including multi-targeted tyrosine kinase inhibitors (TKI), the mammalian target of rapamycin (mTOR) complex-1 kinase inhibitors, and the humanized antivascular endothelial growth factor (VEGF) monoclonal antibody. Hence, the objective of this article was to critically examine the current evidence of targeted therapy treatment for patients with mRCC...
October 2016: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/28138256/radiosynthesis-and-pharmacokinetics-of-18-f-fluoroethyl-bufalin-in-hepatocellular-carcinoma-bearing-mice
#18
Zhaoshuo Yang, Jianhua Liu, Qingqing Huang, Zhouji Zhang, Jiawei Zhang, Yanjia Pan, Yunke Yang, Dengfeng Cheng
PURPOSE: Bufalin, the main component of a Chinese traditional medicine chansu, shows convincing anticancer effects in a lot of tumor cell lines. However, its in vivo behavior is still unclear. This research aimed to evaluate how bufalin was dynamically absorbed after intravenous injection in animal models. We developed a radiosynthesis method of [(18)F]fluoroethyl bufalin to noninvasively evaluate the tissue biodistribution and pharmacokinetics in hepatocellular carcinoma-bearing mice...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28134623/a-ccr4-antagonist-reverses-the-tumor-promoting-microenvironment-of-renal-cancer
#19
Chiara Berlato, Moddasar N Khan, Tiziana Schioppa, Richard Thompson, Eleni Maniati, Anne Montfort, Maryam Jangani, Monica Canosa, Hagen Kulbe, Urs B Hagemann, Alexander R Duncan, Laura Fletcher, Robert W Wilkinson, Thomas Powles, Sergio A Quezada, Frances R Balkwill
Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers. Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnormal levels of CCR4 ligands in RCC patient plasma. An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC. CCR4 inhibition did not reduce the proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myeloid cells, increased NK cell and Th1 cytokine levels, and reduced immature myeloid cell infiltrate and blood chemokine levels...
January 30, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28122358/prognostic-role-of-n-acetylgalactosaminyltransferase-10-in-metastatic-renal-cell-carcinoma
#20
Li Liu, Ying Xiong, Wei Xi, Jiajun Wang, Yang Qu, Zhiyuan Lin, Xiang Chen, Jiaxi Yao, Jiejie Xu, Jianming Guo
BACKGROUND AND PURPOSE: A previous study demonstrated that GALNT10 affects the sensitivity of cancer cells to tyrosine kinase inhibitor (TKI) therapy. The aim of this study was to assess whether GALNT10 holds a prognostic role in metastatic renal cell carcinoma (mRCC) patients treated with TKI agents. RESULTS: GALNT10 had no statistical correlation with any other clinicopathological parameters except for route of gaining samples (P = 0.001) and Heng's risk stratification (P = 0...
January 21, 2017: Oncotarget
keyword
keyword
113910
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"